Nuveen’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.7M | Buy |
46,647
+3,958
| +9% | +$933K | ﹤0.01% | 1457 |
|
|
2026
Q1 | $8.52M | Buy |
42,689
+5,090
| +14% | +$1.01M | ﹤0.01% | 1647 |
|
|
2025
Q4 | $7.11M | Sell |
37,599
-499
| -1% | -$95.9K | ﹤0.01% | 1752 |
|
|
2025
Q3 | $6.75M | Sell |
38,098
-508
| -1% | -$75.5K | ﹤0.01% | 1761 |
|
|
2025
Q2 | $4.39M | Sell |
38,606
-5,690
| -13% | -$608K | ﹤0.01% | 1942 |
|
|
2025
Q1 | $4.66M | Hold |
44,296
| – | – | ﹤0.01% | 1960 |
|
|
2024
Q4 | $4.75M | Hold |
44,296
| – | – | ﹤0.01% | 2010 |
|
|
2024
Q3 | $4.43M | Buy |
44,296
+481
| +1% | +$48.4K | ﹤0.01% | 2042 |
|
|
2024
Q2 | $3.69M | Buy |
43,815
+778
| +2% | +$61.9K | ﹤0.01% | 2096 |
|
|
2024
Q1 | $3.15M | Hold |
43,037
| – | – | ﹤0.01% | 2184 |
|
|
2023
Q4 | $3.07M | Buy |
43,037
+372
| +0.9% | +$22K | ﹤0.01% | 2212 |
|
|
2023
Q3 | $2.56M | Sell |
42,665
-42,314
| -50% | -$2.79M | ﹤0.01% | 2201 |
|
|
2023
Q2 | $6.13M | Buy |
84,979
+20,349
| +31% | +$1.53M | ﹤0.01% | 1800 |
|
|
2023
Q1 | $4.75M | Buy |
64,630
+19,636
| +44% | +$1.4M | ﹤0.01% | 1920 |
|
|
2022
Q4 | $3.01M | Sell |
44,994
-38,198
| -46% | -$2.48M | ﹤0.01% | 2194 |
|
|
2022
Q3 | $4.47M | Sell |
83,192
-2,280
| -3% | -$134K | ﹤0.01% | 1970 |
|
|
2022
Q2 | $4.76M | Sell |
85,472
-1,359
| -2% | -$77.1K | ﹤0.01% | 1981 |
|
|
2022
Q1 | $6.11M | Sell |
86,831
-2,047
| -2% | -$149K | ﹤0.01% | 1953 |
|
|
2021
Q4 | $7.71M | Sell |
88,878
-6,784
| -7% | -$627K | ﹤0.01% | 1843 |
|
|
2021
Q3 | $8.64M | Sell |
95,662
-56,416
| -37% | -$4.36M | ﹤0.01% | 1881 |
|
|
2021
Q2 | $12.4M | Sell |
152,078
-3,193
| -2% | -$266K | ﹤0.01% | 1722 |
|
|
2021
Q1 | $14.8M | Buy |
155,271
+44,444
| +40% | +$4.2M | ﹤0.01% | 1545 |
|
|
2020
Q4 | $6.88M | Sell |
110,827
-3,239
| -3% | -$185K | ﹤0.01% | 1910 |
|
|
2020
Q3 | $6.78M | Sell |
114,066
-3,961
| -3% | -$270K | ﹤0.01% | 1754 |
|
|
2020
Q2 | $8.23M | Sell |
118,027
-71,760
| -38% | -$4.55M | ﹤0.01% | 1621 |
|
|
2020
Q1 | $8.61M | Buy |
189,787
+13,914
| +8% | +$789K | ﹤0.01% | 1389 |
|
|
2019
Q4 | $11.4M | Sell |
175,873
-7,364
| -4% | -$492K | ﹤0.01% | 1508 |
|
|
2019
Q3 | $11.4M | Sell |
183,237
-460
| -0.3% | -$28.9K | ﹤0.01% | 1481 |
|
|
2019
Q2 | $13.1M | Buy |
+183,697
| New | +$13.5M | 0.01% | 1430 |
|
|
2019
Q1 | – | Sell |
-17,625
| Closed | -$1.49M | – | 1064 |
|
|
2018
Q4 | $1.49M | Sell |
17,625
-774
| -4% | -$82.5K | 0.01% | 650 |
|
|
2018
Q3 | $3.15M | Sell |
18,399
-882
| -5% | -$133K | 0.02% | 588 |
|
|
2018
Q2 | $2.49M | Buy |
19,281
+2,767
| +17% | +$309K | 0.02% | 594 |
|
|
2018
Q1 | $1.7M | Buy |
16,514
+1,685
| +11% | +$167K | 0.01% | 640 |
|
|
2017
Q4 | $1.27M | Sell |
14,829
-387
| -3% | -$33.5K | 0.01% | 686 |
|
|
2017
Q3 | $1.29M | Buy |
15,216
+5,220
| +52% | +$413K | 0.01% | 700 |
|
|
2017
Q2 | $757K | Sell |
9,996
-1,554
| -13% | -$109K | ﹤0.01% | 820 |
|
|
2017
Q1 | $763K | Buy |
+11,550
| New | +$760K | ﹤0.01% | 1053 |
|
Other funds holding LGND
JT
CAM
Nuveen's LGND Position: Q2 2026 in Review
Nuveen increased its Ligand Pharmaceuticals (LGND) stake by 9.3% in Q2 2026, buying an estimated $933K and bringing the position to 46,647 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1457.
Nuveen first reported a position in LGND in Q1 2017 and has held it in 37 quarters since. The position peaked at $14.8M in Q1 2021. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Nuveen held 46,647 shares of Ligand Pharmaceuticals worth $14.7M as of Q2 2026.
- Nuveen bought 3,958 Ligand Pharmaceuticals shares in Q2 2026, an estimated $933K.
- Ligand Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1457 holding.
- Nuveen first reported a position in Ligand Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Nuveen's Ligand Pharmaceuticals position peaked at $14.8M in Q1 2021.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.